 |
|
|
| |
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS
|
| |
| |
CROI 2020 March 9
Reported by Jules Levin
Chloe Orkin,1Shinichi Oka,2Patrick Philibert,3Cynthia Brinson,4Ayesha Bassa,5Denis Gusev,6Olaf Degen,7Juan Gonzalez Garcia,8Ronald D'Amico,9David Dorey,10Sandy Griffith,9David A. Margolis,9Marty St. Clair,9Peter Williams,11William R. Spreen9
1Queen Mary University, London, UK; 2National Center for Global Health and Medicine, Tokyo, Japan; 3Hopital Européen, Marseille, France; 4Central Texas Clinical Research, Austin, TX, USA; 5Mzansi Ethical Research Centre, Middelburg, South Africa;6State Medical Center for the Prevention and Control of AIDS and Infectious Diseases, St. Petersburg, Russia; 7University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 8Hospital Universitario La Paz, Madrid, Spain; 9ViiV Healthcare, Research Triangle Park, NC, USA; 10GlaxoSmithKline, Mississauga, ON, Canada; 11Janssen Research & Development, Beerse, Belgium
|
| |
|
|
|
|
|
